Saint-Herblain
(France), June
7,
2022 – Valneva SE (Nasdaq: VALN;
Euronext Paris: VLA), a specialty vaccine company, announced today
it will present on its single-shot chikungunya vaccine candidate
VLA1553 on June 9, 2022 at the 8th Northern European Conference on
Travel Medicine (NECTM8) in Rotterdam.
Vera Bürger, Director Clinical Strategy at
Valneva, will present an abstract on the clinical development of
VLA1553.
In addition, Valneva will host a symposium on
Friday, June 10, 2022 at 12:30 p.m. CEST. The “Technological,
demographic and climate changes: increased risk of mosquito-borne
diseases” symposium will feature Assistant Prof. Johanna Lindahl,
PhD., who will discuss the risk of and protection against mosquito
borne-disease using the example of Japanese encephalitis, and Prof.
Tomas Jelinek, MD, who will focus on chikungunya as a public health
threat.
Valneva, a gold sponsor of NECTM8, will have a
display in the exhibit area at booth #8.
For more details on the presentation, symposium
and conference registration, please visit the event website:
https://mkon.nu/nectm_8.
Presentation Details
Event: 8th Northern European Conference on
Travel Medicine (June 8-10, 2022)
Venue: De Doelen International Conference Center
Rotterdam
Schouwburgplein 50
Rotterdam, The Netherlands
Presentation Title: Clinical Development of a
Live-Attenuated Single-Shot Chikungunya Vaccine Candidate
Date: Thursday, June 9, 2022
Time: 9:00 a.m. CEST
About ChikungunyaChikungunya is
a mosquito-borne viral disease caused by the chikungunya virus
(CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes.
Infection leads to symptomatic disease in 72-92% of humans after
four to seven days following the mosquito bite. While mortality
with CHIKV is low, morbidity is high. Clinical symptoms include
acute onset of fever, debilitating joint and muscle pain, headache,
nausea, rash and chronic arthralgia. Chikungunya virus often causes
sudden large outbreaks with high attack rates, affecting one-third
to three-quarters of the population in areas where the virus is
circulating. The high-risk areas of infection for travelers are
places where chikungunya virus-carrying mosquitos are endemic,
including the Americas, parts of Africa, and Southeast Asia, and
the virus has spread to more than 100 countries. As of September
2020, there were more than three million reported cases in the
Americas1 and the economic impact is considered to be significant.
The medical and economic burden is expected to grow as the CHIKV
primary mosquito vectors continue to spread geographically. There
are no preventive vaccines or effective treatments available and,
as such, chikungunya is considered to be a major public health
threat.
About VLA1553VLA1553 is a
live-attenuated, single dose investigational vaccine candidate
targeting the chikungunya virus, which has spread to over 120
countries. It has been designed by deleting a part of the
chikungunya virus genome.Valneva reported final data from the
pivotal Phase 3 trial of VLA1553 in March 20222 and final
lot-to-lot consistency results in May 20223.VLA1553 would expand
Valneva’s existing commercial vaccines portfolio and as such,
Valneva intends to commercialize this vaccine, if approved,
leveraging its existing manufacturing and commercial operations.
The global market for vaccines against chikungunya is estimated to
exceed $500 million annually by 20324.To make VLA1553 more
accessible to Low and Middle Income Countries (LMIC), Valneva and
Instituto Butantan in Brazil signed an agreement in January 2021
for the development, manufacturing and marketing of VLA15535. The
collaboration falls within the framework of the agreement signed
between CEPI and Valneva in July 20196, which provides funding of
up to $23.4 million with support from the European Union’s Horizon
2020 program.
About Valneva SEValneva is a
specialty vaccine company focused on the development, production
and commercialization of prophylactic vaccines for infectious
diseases with significant unmet medical need. The Company takes a
highly specialized and targeted approach to vaccine development and
then applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to successfully
commercialize two vaccines and to rapidly advance a broad range of
vaccine candidates into and through the clinic, including
candidates against Lyme disease, the chikungunya virus and
COVID-19.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP, Global Communications and European Investor
RelationsM +33 (0)6 4516
7099investors@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor Relations M +001 917 815
4520joshua.drumm@valneva.com |
|
|
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development, clinical trials, and
regulatory review of VLA1553. In addition, even if the actual
results or development of Valneva are consistent with the
forward-looking statements contained in this press release, those
results or developments of Valneva may not be indicative of future
results. In some cases, you can identify forward-looking statements
by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets," or similar words. These forward-looking statements are
based on the current expectations of Valneva as of the date of this
press release and are subject to a number of known and unknown
risks and uncertainties and other factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievement expressed or
implied by these forward-looking statements. In particular, the
expectations of Valneva could be affected by, among other things,
uncertainties involved in the development and manufacture of
vaccines, unexpected clinical trial results, regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, the ability to obtain or
maintain patent or other proprietary intellectual property
protection, the cancellation of existing contracts, including but
not limited to the VLA2001 supply agreement with the UK government,
and the impact of the COVID-19 pandemic, the occurrence of any of
which could substantially harm Valneva’s business, financial
condition, prospects and results of operations. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made during this presentation will in
fact be realized. Valneva is providing the information in this
press release as of the date hereof and disclaims any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
1 PAHO/WHO data: Number of reported cases of chikungunya fever
in the Americas.
https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html.
Last accessed 13 Oct 2020.2 Valneva Successfully Completes Pivotal
Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate3 Valneva
Successfully Completes Lot-to-Lot Consistency Trial for its
Single-Shot Chikungunya Vaccine Candidate4 VacZine Analytics
Chikungunya virus vaccines Global demand analysis. February 20205
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot
Chikungunya Vaccine for Low and Middle Income Countries6 CEPI
awards up to $23.4 million to Valneva for late-stage development of
a single-dose Chikungunya vaccine
- 2022_06_07_VLA_NECTM_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024